However, it has also been reported that RSK4 is overexpressed in >50% of primary malignant lung cancers [64], and RSK3/4 can mediate tumor resistance to PI3 kinase inhibitors in breast cancer [78]. This evidence concerns the gene RPS6KA2 and breast carcinoma.